Drug Interactions between cannabidiol and Prograf
This report displays the potential drug interactions for the following 2 drugs:
- cannabidiol
- Prograf (tacrolimus)
Interactions between your drugs
tacrolimus cannabidiol
Applies to: Prograf (tacrolimus) and cannabidiol
MONITOR: Concomitant use of cannabidiol with calcineurin or mammalian target of rapamycin (mTOR) inhibitors may increase the serum levels of the calcineurin or mTOR inhibitor and the risk of adverse effects. The mechanism for this interaction is not clearly understood. There have been literature reports describing increased serum levels of sirolimus, everolimus, or tacrolimus with coadministration of cannabidiol.
MANAGEMENT: Although the interaction has not been studied, caution is advised if cannabidiol is coadministered with calcineurin or mTOR inhibitors. Clinical and laboratory monitoring should be considered whenever cannabidiol is added to or withdrawn from therapy with a calcineurin or mTOR inhibitor, and the dosage of the calcineurin or mTOR inhibitor adjusted as necessary. Patients should be monitored for development of adverse effects associated with the calcineurin or mTOR inhibitor.
References (1)
- (2018) "Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC
Drug and food interactions
tacrolimus food
Applies to: Prograf (tacrolimus)
ADJUST DOSING INTERVAL: Consumption of food has led to a 27% decrease in the bioavailability of orally administered tacrolimus.
MANAGEMENT: Tacrolimus should be administered at least one hour before or two hours after meals.
GENERALLY AVOID: Grapefruit juice has been reported to increase tacrolimus trough concentrations. Data are limited, but inhibition of the CYP450 enzyme system appears to be involved.
MANAGEMENT: The clinician may want to recommend that the patient avoid ingesting large amounts of grapefruit juice while taking tacrolimus.
References (2)
- (2001) "Product Information. Prograf (tacrolimus)." Fujisawa
- Hooks MA (1994) "Tacrolimus, a new immunosuppressant--a review of the literature." Ann Pharmacother, 28, p. 501-11
cannabidiol food
Applies to: cannabidiol
ADJUST DOSING INTERVAL: Food may affect the plasma concentrations of cannabidiol. In healthy volunteers, administration of cannabidiol with a high-fat/high-calorie meal increased cannabidiol peak plasma concentration (Cmax) by 5-fold and systemic exposure (AUC) by 4-fold and reduced the total variability compared with administration in the fasted state.
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of cannabidiol. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of cannabidiol by certain compounds present in grapefruit. The interaction has not been studied, but the product labeling for cannabidiol recommends consideration of a dosage reduction when used with strong or moderate inhibitors of CYP450 3A4. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition.
MANAGEMENT: Cannabidiol should be taken about the same time each day consistently either with or without food. Patients should limit the consumption of grapefruit and grapefruit juice. If they are coadministered, cannabidiol levels should be monitored and the dosage adjusted as necessary.
References (1)
- (2018) "Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.